120 related articles for article (PubMed ID: 1888150)
1. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results.
Bartholeyns J; Lopez M; Andreesen R
Anticancer Res; 1991; 11(3):1201-4. PubMed ID: 1888150
[TBL] [Abstract][Full Text] [Related]
2. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
3. Immune control of neoplasia by adoptive transfer of macrophages: potentiality for antigen presentation and gene transfer.
Bartholeyns J; Lopez M
Anticancer Res; 1994; 14(6B):2673-6. PubMed ID: 7872699
[TBL] [Abstract][Full Text] [Related]
4. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Leser HG; Kopf S; Engler H; Schümichen C; Löhr GW
Cancer Detect Prev; 1991; 15(5):413-21. PubMed ID: 1751953
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
6. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
7. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
8. The role of interleukin-2 in cancer immunotherapy.
Eberlein TJ; Schoof DD
Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612
[TBL] [Abstract][Full Text] [Related]
9. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of cancer: experimental approach with activated macrophages proliferating in culture.
Bartholeyns J; Lombard Y; Dumont S; Hartmann D; Chokry M; Giaimis J; Kaufmann S; Poindron P
Cancer Detect Prev; 1988; 12(1-6):413-20. PubMed ID: 3180139
[TBL] [Abstract][Full Text] [Related]
11. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
12. Tumor-cytolytic human macrophages cultured as nonadherent cells: potential for the adoptive immunotherapy of cancer.
Helinski EH; Hurley EL; Streck RJ; Bielat KL; Pauly JL
Cancer Detect Prev; 1990; 14(4):471-81. PubMed ID: 2224910
[TBL] [Abstract][Full Text] [Related]
13. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
15. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of cancer: accomplishments and prospects.
Rosenberg SA
Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
[TBL] [Abstract][Full Text] [Related]
17. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
19. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]